SKF82958, a dopamine D1 receptor agonist, disrupts prepulse inhibition in the medial prefrontal cortex and nucleus accumbens in C57BL/6J mice.
| Autor: | Yang C; Key Laboratory of Cognition and Personality (Southwest University), Ministry of Education.; Faculty of Psychology, Southwest University., Chen X; Key Laboratory of Cognition and Personality (Southwest University), Ministry of Education.; Faculty of Psychology, Southwest University., Xu J; Westa College, Southwest University, Chongqing, China., Chen W; Key Laboratory of Cognition and Personality (Southwest University), Ministry of Education.; Faculty of Psychology, Southwest University. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Behavioural pharmacology [Behav Pharmacol] 2024 Jun 01; Vol. 35 (4), pp. 193-200. Date of Electronic Publication: 2024 Mar 29. |
| DOI: | 10.1097/FBP.0000000000000768 |
| Abstrakt: | Prepulse inhibition (PPI) is a crucial indicator of sensorimotor gating that is often impaired in neuropsychiatric diseases. Although dopamine D1 receptor agonists have been found to disrupt PPI in mice, the underlying mechanisms are not fully understood. In this study, we aimed to identify the brain regions responsible for the PPI-disruptive effect of the D1 agonist in mice. Results demonstrated that intraperitoneal administration of the selective dopamine D1 receptor agonist SKF82958 dramatically inhibited PPI, while the dopamine D1 receptor antagonist SCH23390 enhanced PPI. Additionally, local infusion of SKF82958 into the nucleus accumbens and medial prefrontal cortex disrupted PPI, but not in the ventral hippocampus. Infusion of SCH23390 into these brain regions also failed to enhance PPI. Overall, the study suggests that the nucleus accumbens and medial prefrontal cortex are responsible for the PPI-disruptive effect of dopamine D1 receptor agonists. These findings provide essential insights into the cellular and neural circuit mechanisms underlying the disruptive effects of dopamine D1 receptor agonists on PPI and may contribute to the development of novel treatments for neuropsychiatric diseases. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|